Results 71 to 80 of about 75,185 (305)

Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease [PDF]

, 2017
Alterations of the dopaminergic (DAergic) system are frequently reported in Alzheimer’s disease (AD) patients and are commonly linked to cognitive and non-cognitive symptoms. However, the cause of DAergic system dysfunction in AD remains to be elucidated.
Aversa, D, Berretta, N, Cavallucci, V, Coccurello, R, Cordella, A, Cutuli, Debora, D'Amelio, M., De Bartolo, P, Dell'Acqua, Mc, Federici, M, Giacovazzo, G, Keller, F, Krashia, P, Latagliata, EMANUELE CLAUDIO, Marino, R, Mercuri, Nb, Nobili, A, Petrosini, Laura, PUGLISI ALLEGRA, Stefano, Rizzo, Fr, Sancandi, M, Viscomi, Mt   +21 more
core   +3 more sources

Chiral‐Encoded Pt‐Ir Surfaces as Apparent Spin Filter for Enhanced Oxygen Reduction

Advanced Science, EarlyView.
The Chiral‐Induced Spin Selectivity (CISS) effect is employed in chiral‐encoded mesoporous Platinum‐Iridium (Pt‐Ir) electrocatalysts to enhance the oxygen reduction reaction (ORR). A break in spin symmetry leads to a substantial antagonistic difference in activity (>200%) when comparing two enantiomorphs of the same electrode.
Zikkawas Pasom, Krissanapat Yomthong, Sopon Butcha, Jonas Fransson, Chularat Wattanakit, Alexander Kuhn   +5 more
wiley   +1 more source

L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain

Parkinson's Disease, 2012
Astrocyte endfeet surround brain blood vessels and can play a role in the delivery of therapeutic drugs for Parkinson’s disease. However, there is no previous evidence of the presence of LAT transporter for L-DOPA in brain astrocytes except in culture ...
M. Y. Inyushin, A. Huertas, Y. V. Kucheryavykh, L. Y. Kucheryavykh, V. Tsydzik, P. Sanabria, M. J. Eaton, S. N. Skatchkov, L. V. Rojas, W. D. Wessinger   +9 more
doaj   +1 more source

Effects of Subchronic Treatment With Selegiline on L-DOPA-Induced Increase in Extracellular Dopamine Level in Rat Striatum

Journal of Pharmacological Sciences, 2006
.: Selegiline is used an adjunct to L-DOPA therapy. We investigated extracellular striatal dopamine (DA) level in awake rats treated with L-DOPA and/or selegiline using a microdialysis method. Rats given 10 mg/kg, i.p.
Adachi Kouichi, Miwa Hideto, Kusumoto Haruko, Shimazu Seiichiro, Kondo Tomoyoshi   +4 more
doaj   +1 more source

Estudo eletroquímico e determinação de l-dopa em produto farmacêutico por voltametria cíclica [PDF]

, 2006
TCC (graduação) - Universidade Federal de Santa Catarina. Centro de Ciências Físicas e Matemáticas. Curso de Química.Estudou-se o comportamento eletroquímico da L-dopa em solução de acetato de sódio 0,1 mol L-1, pH 3,0, v = 100 mVs-1 e fez-se a ...
SILVA, Lidiane Almeida da
core  

Betalain production is possible in anthocyanin-producing plant species given the presence of DOPA-dioxygenase and L-DOPA [PDF]

, 2012
Background Carotenoids and anthocyanins are the predominant non-chlorophyll pigments in plants. However, certain families within the order Caryophyllales produce another class of pigments, the betalains, instead of anthocyanins.
Harris Nilangani N, Javellana John, Davies Kevin M, Lewis David H, Jameson Paula E, Deroles Simon C, Calcott Kate E, Gould Kevin S, Schwinn Kathy E   +8 more
core   +1 more source

Development of a Human 3D Immune‐Competent Neurovascular Model Enabling Time‐Resolved Monitoring of Neuroinflammatory Dynamics and Neuroimmune Interactions

Advanced Science, EarlyView.
Neuroinflammation alters blood–brain barrier integrity and contributes to neurological disorders, yet existing models lack human immune complexity. This study presents a 3D, immune‐responsive platform that reconstructs key neurovascular components and enables real‐time monitoring.
Pavlo Gordiichuk, Jing Bai, Olurotimi A. Bolonduro, Andrew M. Silverman, Robert Madison Green, Jason H. Lasser, Paul W. Fleming, Lishomwa C. Ndhlovu, James F. Saunders, Dmitry Shvartsman   +9 more
wiley   +1 more source

The Effect of Chronic Treatment with the Inhibitor of Phosphodiesterase 5 (PDE5), Sildenafil, in Combination with L-DOPA on Asymmetric Behavior and Monoamine Catabolism in the Striatum and Substantia Nigra of Unilaterally 6-OHDA-Lesioned Rats

Molecules
The use of phosphodiesterase inhibitors in the treatment of Parkinson’s disease is currently widely discussed. The study aimed to investigate the impact of acute and chronic treatment with the phosphodiesterase 5 inhibitor, sildenafil, at low and ...
Elżbieta Lorenc-Koci, Kinga Kamińska, Tomasz Lenda, Jolanta Konieczny   +3 more
doaj   +1 more source

Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

Journal of Parkinson’s Disease, 2022
Background: L-DOPA-induced dyskinesia (LID), occurring with aberrant processing of exogenous L-DOPA in the dopamine-denervated striatum, is a main complication of levodopa treatment in Parkinson’s disease.
Kuan-Yin Tseng, Tung-Tai Kuo, Vicki Wang, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Lars Olson, Barry J. Hoffer, Yuan-Hao Chen   +7 more
doaj   +1 more source

Hypotension Caused by L-Dopa [PDF]

BMJ, 1970
In 20 patients with idiopathic Parkinsonism maximum tolerated doses of L-dopa were found to induce a mean reduction in blood pressure (erect systolic) of 19·3 mm.Hg, without any significant change in pulse rate. This hypotension may be due to dopamine, acting on adrenergic nerve endings or on the central nervous system itself.
D B, Calne, J, Brennan, A S, Spiers, G M, Stern   +3 more
openaire   +2 more sources